Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69472 | 0.90 | GAA (0.57) | POLBGAAMAPTALDH1A1CA12 | |
| SCHEMBL7206333 | 0.82 | HTR6 (0.58) | HTR6POLBGAAMAPTALDH1A1 | |
| SCHEMBL1346857 | 0.82 | HTR6 (0.58) | HTR6POLBGAAGFERMAPT | |
| SCHEMBL8057512 | 0.80 | GAA (0.63) | HTR6POLBGAAGFERMAPT | |
| SCHEMBL8057506 | 0.80 | GAA (0.63) | HTR6POLBGAAGFERMAPT | |
| SCHEMBL660467 | 0.79 | GAA (0.73) | HTR6POLBGAAGFERMAPT | |
| SCHEMBL6534882 | 0.79 | GAA (0.73) | HTR6POLBGAAGFERMAPT | |
| SCHEMBL21487215 | 0.78 | CA2 (0.63) | GAAMAPTCA12CA1CA2 | |
| SCHEMBL9805864 | 0.78 | HTR6 (0.52) | HTR6POLBGAAGFERMAPT | |
| SCHEMBL565124 | 0.78 | GAA (0.81) | HTR6POLBGAAGFERMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-100540546-C | Be used to regulate 5-HT6 acceptor, 5-HT2A acceptor or both aryl sulfonyl benzos two alkane | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| CN-1960983-A | Arylsulfonyl benzodioxanes useful for modulation the 5-HT6 receptor, the 5-HT2areceptor or both | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1748995-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. Hoffmann-La Roche AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105776-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | HTR6, HTR7, HTR1F | HTR6 1/4885POLB 4372/4885GAA 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.